MedTrace Logo

Photocil (Topical) for the Treatment of Atopic Dermatitis

NCT01992172 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2016-03-25

Study results available
· View outcomes & findings →

Summary

Photocil is a topical drug (cream) that selectively delivers Narrow Band - Ultraviolet B (NB-UVB) therapy when exposed to sunlight. Photocil is intended to help protect users from non-therapeutic Ultraviolet B (UVB) radiation while selectively passing wavelengths of light in the NB-UVB range with peak transmission of 308nm. The aim of the study is to assess the safety and efficacy of Photocil in the treatment of atopic dermatitis.

Conditions

Interventions

DRUG

Photocil for Atopic Dermatitis

Photocil for Atopic Dermatitis

OTHER

Placebo - Sunscreen (SPF 2)

Placebo - Sunscreen (SPF 2)

Sponsors & Collaborators

  • Applied Biology, Inc.

    lead INDUSTRY

Principal Investigators

  • John McCoy, PhD · Applied Biology, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01992172 on ClinicalTrials.gov